Business Wire

NuScale and Nuclearelectrica Reach Agreement at COP26 to Initiate the Deployment of the First Small Modular Reactor in Europe

4.11.2021 20:13:00 EET | Business Wire | Press release

Share

At the United Nations Conference on Climate Change (COP26), U.S. Secretary of Energy Jennifer M. Granholm, U.S. Department of Energy, and Romania’s Minister of Energy, Virgil Popescu, highlighted that earlier today NuScale Power and Romania’s S.N. Nuclearelectrica S.A. signed a teaming agreement to advance the deployment of NuScale’s innovative small modular reactor (SMR) technology. Following the partnership, Romania has the potential to accommodate the first deployment of SMRs in Europe and to become a catalyst for SMRs in the region, as well as a base for supporting operatorship of this new technology in other countries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104006088/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cosmin Ghita, Chief Executive Officer, Nuclearelectrica and John Hopkins, Chairman and Chief Executive Officer, NuScale Power (Photo: Business Wire)

The teaming agreement between NuScale Power, whose SMR is the first and only small modular reactor to receive design approval from the U.S. Nuclear Regulatory Commission, and Nuclearelectrica, a Romanian nuclear energy producer, comes at a pivotal time as senior government policymakers from around the world discuss the urgency of accelerating the clean energy transition. Discussion at the signing ceremony echoed this call to action and reinforced how NuScale’s SMRs can support international climate goals, help mitigate the worst impacts of climate change, and strengthen global prosperity.

Under the teaming agreement, NuScale will help Nuclearelectrica evaluate its technology, and together, the organizations will take steps toward deploying a first NuScale 6-module, 462 MWe, power plant in Romania as early as 2027/2028. The NuScale 6-module power plant is estimated to generate 193 permanent power plant jobs, 1,500 construction jobs, 2,300 manufacturing jobs and help Romania avoid 4M tons of CO2 emissions per year.

“The United States views nuclear energy as a pivotal technology in the global effort to lower emissions, expand economic opportunity, and ultimately combat climate change,” U.S. Secretary of Energy Jennifer M. Granholm. “We have been supporting the development of SMRs for decades, and it is extremely gratifying to celebrate this important milestone for Romania to help them achieve their climate goals.”

“Based on the Integrated National Plan in the field of Energy and Climate Change (PNIESC), Romania plans to reduce CO2 emissions by 55% until 2030 and its import dependency from 20.8% today to 17.8% in 2030. Nuclear energy has an essential role in achieving these decarbonization targets and ensuring the energy transition to a carbon-free economy, currently contributing 33% in total CO2-free energy production. After the implementation of strategic investment projects, this contribution will increase exponentially, while also ensuring energy security for Romania and the region. Building and operating small modular reactors will have proven environmental benefits of clean, emissions-free energy, bringing direct socio-economic benefits to the community it serves and generating continued prosperity for the regional industry and economy. We aim to develop the first SMR this decade in order to meet our critical energy demand and green targets securing a quality future for the generations to come. Decarbonation with nuclear is possible! I salute and support the signing of the teaming between the two companies, based on the long history of our two countries. The bilateral relations between Romania and the USA in the nuclear field started in the 1980s and since then they bring numerous benefits, most importantly economic stability and energy security. I thank our American partners and Secretary Granholm for supporting and endorsing the nuclear programs,” said Virgil Popescu, Minister of Energy, Romania.

“As Romania aims to diversify its energy portfolio and meet climate goals, NuScale’s advanced technology presents the perfect safe, economic and scalable solution,” said John Hopkins, NuScale Power Chairman and Chief Executive Officer. “While world leaders emphasize how critical this moment is in addressing climate change, NuScale’s SMR technology not only represents a pathway to meet Romania’s climate commitments, but also is a means to bolster local economic growth. NuScale is excited to work with Nuclearelectrica and to showcase the many benefits our technology will bring.”

“Nuclearelectrica is proud to be at the lead, valuing its experience operating at excellent standards and one of the highest performing nuclear plants in the world, into developing the first SMRs in Europe, an energy source that is 100% carbon free and which will reduce environmental footprints and put us on a path toward a zero-emission world. And at the same time, will form a new generation of engineers, which will benefit from the 25 years of experience Nuclearelectrica has and the groundbreaking innovation of NuScale’s SMR technology. What exciting times to contribute to the future of energy, to build a clean legacy for the generations to come,” Cosmin Ghita, Chief Executive Officer, Nuclearelectrica.

Watch the Signing Ceremony

Specifically, the teaming agreement outlines the next significant milestones for Nuclearelectrica and NuScale to develop safe, affordable zero-carbon baseload power technology with a focus on retired coal plant sites. It will support the Government of Romania’s National Recovery and Resilience Plan to phase out 4.59 GWe of coal fired energy production by 2032. By repurposing coal plants, Nuclearelectrica and NuScale can help communities and plant workers participate in the transition to decarbonized energy, while also continuing to provide local economic benefits. This teaming agreement serves as a catalyst for deployments in other Three Seas Initiative countries seeking to decarbonize.

This agreement follows a memorandum of understanding (MOU) signed between Nuclearelectrica and NuScale in 2019 to evaluate the development, licensing and construction of a NuScale SMR in Romania. The new teaming agreement advances the commitment to facilitate the deployment of a NuScale SMR in Romania.

In August 2020, NuScale made history as the first and only SMR to receive design approval from the U.S. Nuclear Regulatory Commission—a crucial step towards the construction and deployment of this SMR technology. The company maintains strong program momentum toward commercialization of its SMR technology, including supply chain development, standard plant design, planning of plant delivery activities, and startup and commissioning plans.

About NuScale Power

NuScale Power has developed a new modular light water reactor nuclear power plant to supply energy for electrical generation, district heating, desalination, hydrogen production and other process heat applications. This groundbreaking small modular reactor (SMR) design features a fully factory-fabricated NuScale Power Module™ capable of generating 77 MW of electricity using a safer, smaller, and scalable version of pressurized water reactor technology. NuScale's scalable design—power plants that can house up to four, six, or twelve individual power modules—offers the benefits of carbon-free energy and reduces the financial commitments associated with gigawatt-sized nuclear facilities. The majority investor in NuScale is Fluor Corporation, a global engineering, procurement, and construction company with a 70-year history in commercial nuclear power.

NuScale is headquartered in Portland, OR, and has offices in Corvallis, OR; Rockville, MD; Charlotte, NC; Richland, WA; and London, UK. Follow us on Twitter: @NuScale_Power, Facebook: NuScale Power, LLC, LinkedIn: NuScale-Power, and Instagram: nuscale_power. Visit NuScale Power's website.

About Nuclearelectrica

The National Company “Nuclearelectrica” S.A. is the national Romanian company producing electricity, heat and nuclear fuel, which operates under the authority of the Romanian Ministry of Energy, the state holding 82.49% of shares and other shareholders, 17.50%, after the listing of the company on the stock exchange in 2013.

Cernavoda NPP Branch operates two CANDU nuclear units, which are two of the most performant units among more than 400 nuclear power plants in the world, a nuclear fuel factory and is in the process of achieving an integrated fuel cycle by acquiring an uranium concentrate processing line to support the company's long-term investment projects.

Nuclearelectrica has a major role at the national level, contributing over 18% of nuclear energy in total energy production and 33% in total CO2-free energy production in Romania.

www.nuclearelectrica.ro

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Diane Hughes, Vice President, Marketing & Communications, NuScale Power
dhughes@nuscalepower.com
(C) (503) 270-9329

Tones Ludmila, Advisor of CEO, S.N. Nuclearelectrica
Ludmila.Tones@nuclearelectrica.ro
0040-730044468

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye